Have your own idea? Try our Stock Screener
U.S. Biotech Industry Analysis
UpdatedNov 07, 2025
DataAggregated Company Financials
Companies541
- 7D0.8%
- 3M16.4%
- 1Y0.3%
- YTD15.5%
Last week, the Biotech industry hasn't moved much but Amgen is up 8.1% in that time. Furthermore, the industry has been flat for the past year as well. As for the next few years, earnings are expected to grow by 24% per annum.
Industry Valuation and Performance
Has the U.S. Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Fri, 07 Nov 2025 | US$1.1t | US$163.0b | -US$15,959,392,425.08 | 16.2x | -71.1x | 7x |
| Sun, 05 Oct 2025 | US$1.1t | US$163.5b | -US$18,204,873,215.17 | 16.7x | -62.3x | 6.9x |
| Tue, 02 Sep 2025 | US$1.1t | US$163.5b | -US$18,373,948,947.11 | 15.4x | -57.4x | 6.5x |
| Thu, 31 Jul 2025 | US$978.1b | US$155.2b | -US$22,154,473,663.94 | 15.9x | -44.2x | 6.3x |
| Sat, 28 Jun 2025 | US$928.6b | US$156.0b | -US$23,836,878,936.09 | 17.2x | -39x | 6x |
| Mon, 26 May 2025 | US$907.6b | US$155.9b | -US$24,118,382,442.03 | 15.6x | -37.6x | 5.8x |
| Wed, 23 Apr 2025 | US$752.0b | US$119.2b | -US$36,420,549,137.23 | 19.6x | -20.6x | 6.3x |
| Fri, 21 Mar 2025 | US$837.9b | US$118.6b | -US$37,243,662,257.91 | 20x | -22.5x | 7.1x |
| Sun, 16 Feb 2025 | US$842.2b | US$116.6b | -US$36,838,613,842.21 | 17.6x | -22.9x | 7.2x |
| Tue, 14 Jan 2025 | US$947.8b | US$149.4b | -US$26,259,951,633.40 | 17.1x | -36.1x | 6.3x |
| Thu, 12 Dec 2024 | US$1.0t | US$150.0b | -US$26,538,399,035.48 | 17.5x | -38.6x | 6.8x |
| Sat, 09 Nov 2024 | US$1.1t | US$149.6b | -US$27,181,635,977.17 | 16.5x | -40.5x | 7.4x |
| Mon, 07 Oct 2024 | US$889.8b | US$113.1b | -US$35,952,253,973.77 | 22x | -24.8x | 7.9x |
| Wed, 04 Sep 2024 | US$909.4b | US$113.1b | -US$35,700,641,712.66 | 23x | -25.5x | 8x |
| Fri, 02 Aug 2024 | US$1.2t | US$165.2b | -US$29,241,766,364.50 | 30.6x | -42x | 7.4x |
| Sun, 30 Jun 2024 | US$1.1t | US$164.4b | -US$27,988,781,321.07 | 28.5x | -41x | 7x |
| Tue, 28 May 2024 | US$1.1t | US$164.6b | -US$26,662,546,931.62 | 27.2x | -42.2x | 6.8x |
| Thu, 25 Apr 2024 | US$1.1t | US$164.1b | -US$23,434,274,940.24 | 20.4x | -46.7x | 6.7x |
| Sat, 23 Mar 2024 | US$1.2t | US$164.3b | -US$23,951,750,761.50 | 21.3x | -48.5x | 7.1x |
| Mon, 19 Feb 2024 | US$1.2t | US$169.1b | -US$20,519,191,458.58 | 15.7x | -56.9x | 6.9x |
| Wed, 17 Jan 2024 | US$1.4t | US$204.7b | -US$22,509,124,769.00 | 18.9x | -63.9x | 7x |
| Fri, 15 Dec 2023 | US$1.3t | US$204.8b | -US$22,109,997,154.00 | 19.2x | -61.1x | 6.6x |
| Sun, 12 Nov 2023 | US$1.2t | US$204.5b | -US$22,004,263,459.00 | 18.5x | -54.5x | 5.9x |
| Tue, 10 Oct 2023 | US$1.3t | US$207.4b | -US$13,078,903,969.00 | 17.1x | -96.1x | 6.1x |
| Thu, 07 Sep 2023 | US$1.3t | US$207.5b | -US$12,633,134,897.00 | 16.9x | -100.5x | 6.1x |
| Sat, 05 Aug 2023 | US$1.3t | US$210.2b | -US$10,152,777,050.00 | 15.6x | -124.1x | 6x |
| Mon, 03 Jul 2023 | US$1.1t | US$186.2b | -US$16,042,400,813.00 | 13.7x | -70x | 6x |
| Wed, 31 May 2023 | US$1.1t | US$185.9b | -US$15,975,506,164.00 | 11.3x | -69.7x | 6x |
| Fri, 28 Apr 2023 | US$1.1t | US$198.5b | -US$3,342,494,771.00 | 13.1x | -342.6x | 5.8x |
| Sun, 26 Mar 2023 | US$1.1t | US$199.3b | -US$3,673,370,952.00 | 13.4x | -308.5x | 5.7x |
| Tue, 21 Feb 2023 | US$1.2t | US$202.6b | -US$118,851,937.00 | 16.5x | -9707x | 5.7x |
| Thu, 19 Jan 2023 | US$1.2t | US$203.6b | US$1.8b | 14.5x | 661.6x | 5.7x |
| Sat, 17 Dec 2022 | US$1.2t | US$203.3b | US$1.6b | 14.4x | 709.9x | 5.7x |
| Mon, 14 Nov 2022 | US$1.1t | US$202.2b | US$1.1b | 14.6x | 1002.6x | 5.5x |
Price to Earnings Ratio
1002.6x
Current Industry PE
- Investors are relatively neutral on the American Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.
- The industry is trading close to its 3-year average PS ratio of 6.5x.
Past Earnings Growth
- Total earnings for the Biotechs industry have declined over the last three years, with the industry now making a loss overall.
- Revenues have also declined 6.9% per year, which is driving profits down.
Industry Trends
Which industries have driven the changes within the U.S. Healthcare industry?
| US Market | -1.75% | |
| Healthcare | 1.03% | |
| Biotech | 0.81% | |
| Biotech | 0.81% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| AMGN Amgen | US$315.59 | 8.1% +US$12.7b | -2.0% | PE24.3x | |
| GILD Gilead Sciences | US$123.40 | 4.2% +US$6.2b | 26.0% | PE18.9x | |
| ONC BeOne Medicines | US$332.36 | 7.8% +US$2.7b | 60.7% | PS8x | |
| INCY Incyte | US$105.20 | 13.6% +US$2.5b | 27.8% | PE17.4x | |
| MTSR Metsera | US$81.55 | 28.0% +US$1.9b | n/a | PB19.1x |